Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.34 |
| ▸ | LOX | P28300 | 1/20 | 0.33 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11503357 | 1.00 | TSHR (0.43) | TSHRALDH1A1TDP1MAPTHIF1A | |
| SCHEMBL2299758 | 1.00 | — | — | |
| SCHEMBL2537877 | 1.00 | TSHR (0.43) | TSHRALDH1A1TDP1MAPTHIF1A | |
| SCHEMBL15767254 | 1.00 | TSHR (0.43) | TSHRALDH1A1TDP1MAPTHIF1A | |
| SCHEMBL2296137 | 1.00 | — | — | |
| SCHEMBL15767038 | 1.00 | TSHR (0.43) | TSHRALDH1A1TDP1MAPTHIF1A | |
| SCHEMBL366051 | 0.97 | — | — | |
| SCHEMBL246676 | 0.87 | — | — | |
| SCHEMBL1003333 | 0.83 | ALDH1A1 (0.58) | TSHRALDH1A1TDP1MAPTHIF1A | |
| SCHEMBL645518 | 0.83 | ALDH1A1 (0.58) | TSHRALDH1A1TDP1MAPTHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11320739-B2 | Composition for resist underlayer film formation, resist underlayer film and method for producing patterned substrate | JSR CORPORATION (JP) | 2022-05-03 | — | — | US | claimed |
| US-11320739-B2 | Composition for resist underlayer film formation, resist underlayer film and method for producing patterned substrate | JSR CORPORATION (JP) | 2022-05-03 | — | — | US | disclosed |
| US-20180348633-A1 | COMPOSITION FOR RESIST UNDERLAYER FILM FORMATION, RESIST UNDERLAYER FILM AND METHOD FOR PRODUCING PATTERNED SUBSTRATE | JSR CORPORATION (JP) | 2018-12-06 | — | — | US | disclosed |
| US-9040516-B2 | Uracil derivative and use thereof for medical purposes | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20140179670-A1 | URACIL DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
| EP-2740728-A1 | URACIL DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2014-06-11 | — | — | EP | disclosed |
| US-8044070-B2 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2011-10-25 | — | — | US | disclosed |
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | MSD K.K. (JP) | 2010-08-19 | — | — | US | disclosed |
| US-7595316-B2 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-09-29 | — | — | US | disclosed |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1642898-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | HRH3, HRH4, HCRTR2 | TSHR 226/4885ALDH1A1 3756/4885TDP1 4743/4885 |
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | HRH3, HRH4, HRH2 | TSHR 223/4885ALDH1A1 2837/4885TDP1 4726/4885 |
| US-20140179670-A1 | URACIL DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | URB2, ELANE, NUDT1 | TSHR 3016/4885ALDH1A1 171/4885TDP1 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.